Pathogenesis and treatment of Ph+ leukemia: Recent insights from mouse models

Current Opinion in Hematology

Volumn 8, Issue 4, 2001, Pages 224-230

  Van Etten, Richard A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

B CELL LEUKEMIA; BONE MARROW; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MICE, TRANSGENIC; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034889951     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200107000-00008     Document Type: Review

References (56)

1. Animal models of Philadelphia-positive leukemia
2. Models of chronic myeloid leukemia
3. In vive eradication of human BCR/ABL positive leukemia cells with an ABL kinase inhibitor
4. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the Abl inhibitor ST1571
5. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
6. Oncogene inactivation in a mouse model
7. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model
8. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy
9. Propagation of human blastic myeloid leukemias in the SCID mouse
10. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias
11. Differential growth patterns in SCID mice of patient-derived chronic myelogenous leukemias
12. Normal and leukemic SCID- repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis
13. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: An in vive model of chronic myelogenous leukemia biology
14. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase
15. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells
16. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
17. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia
18. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
19. The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase
20. A bcr-v-abl oncogene induces lymphomas in transgenic mice
21. Human bcr-abl gene has a lethal effect on embryogenesis
22. Acute leukemia in bcr/abl transgenic mice
23. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
24. Restricted oncogenicity of BCR/ABL p190 in transgenic mice
25. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl
26. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta
27. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase
28. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
29. Early events in leukemogenesis in P190Bcr-abl transgenic mice
30. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice
31. Reduced encegenicity of p190 Bcr/Abl F-actin-binding domain mutants
32. Bcr/Abl associated leukemogenesis in bcr null mutant mice
33. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice
34. Treatment of Bcr/Abl-positive ALL in p190 transgenic mice with the farnesyltransferase inhibitor SCH66336
35. Activity of a specific inhibitor of the BCR-ABL tyresine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
36. 1-positive leukemias
37. Acquired loss of p53 induces biastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML
38. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
39. Regulated expression of p210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate
40. bcr/abl gene of the Philadelphia chromosome
41. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
42. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
43. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
44. Retroviral transduction models of Ph+ leukemia: Advantages and limitations for modeling human hematological malignancies in mice
45. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of STAT5
46. STAT5 is essentlal for the myelo- and lymphoproliferative disease induced by TEL/JAK2
47. Autocrine production and action of IL-3 and granuolcyte colony-stimulating factor in chronic myeloid leukemia
48. Interleukin-3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferatlve disease in mice by BCR/ABL
49. 2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl
50. The Grb2 binding site is required for induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
51. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
52. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
53. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid progenitor cells
54. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway
55. The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype